Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma
Asthma is a major respiratory disorder characterised by chronic inflammation and airway remodelling. It affects about 1–8% of the global population and is responsible for over 461,000 deaths annually. Until recently, the pharmacotherapy of severe asthma involved high doses of inhaled corticosteroids...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
Academic Press
2022
|
| _version_ | 1796984186913947648 |
|---|---|
| author | Okwuofu, Emmanuel Oshiogwe Chee, Audrey Hui Yong Chee, Jonathan Woei Lim Stanslas, Johnson |
| author_facet | Okwuofu, Emmanuel Oshiogwe Chee, Audrey Hui Yong Chee, Jonathan Woei Lim Stanslas, Johnson |
| author_sort | Okwuofu, Emmanuel Oshiogwe |
| collection | UPM |
| description | Asthma is a major respiratory disorder characterised by chronic inflammation and airway remodelling. It affects about 1–8% of the global population and is responsible for over 461,000 deaths annually. Until recently, the pharmacotherapy of severe asthma involved high doses of inhaled corticosteroids in combination with β-agonist for prolonged action, including theophylline, leukotriene antagonist or anticholinergic yielding limited benefit. Although the use of newer agents to target Th2 asthma endotypes has improved therapeutic outcomes in severe asthmatic conditions, there seems to be a paucity of understanding the diverse mechanisms through which these classes of drugs act. This article delineates the molecular and immunomodulatory mechanisms of action of new antiasthmatic agents currently being trialled in preclinical and clinical studies to remit asthmatic conditions. The ultimate goal in developing antiasthmatic agents is based on two types of approaches: either anti-inflammatory or bronchodilators. Biologic and most small molecules have been shown to modulate specific asthma endotypes, targeting thymic stromal lymphopoietin, tryptase, spleen tyrosine kinase (Syk), Janus kinase, PD-L1/PD-L2, GATA-3, and CD38 for the treatment and management of Th2 endotype asthma. |
| first_indexed | 2024-03-06T11:16:54Z |
| format | Article |
| id | upm.eprints-102223 |
| institution | Universiti Putra Malaysia |
| last_indexed | 2024-03-06T11:16:54Z |
| publishDate | 2022 |
| publisher | Academic Press |
| record_format | dspace |
| spelling | upm.eprints-1022232023-07-11T01:22:03Z http://psasir.upm.edu.my/id/eprint/102223/ Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma Okwuofu, Emmanuel Oshiogwe Chee, Audrey Hui Yong Chee, Jonathan Woei Lim Stanslas, Johnson Asthma is a major respiratory disorder characterised by chronic inflammation and airway remodelling. It affects about 1–8% of the global population and is responsible for over 461,000 deaths annually. Until recently, the pharmacotherapy of severe asthma involved high doses of inhaled corticosteroids in combination with β-agonist for prolonged action, including theophylline, leukotriene antagonist or anticholinergic yielding limited benefit. Although the use of newer agents to target Th2 asthma endotypes has improved therapeutic outcomes in severe asthmatic conditions, there seems to be a paucity of understanding the diverse mechanisms through which these classes of drugs act. This article delineates the molecular and immunomodulatory mechanisms of action of new antiasthmatic agents currently being trialled in preclinical and clinical studies to remit asthmatic conditions. The ultimate goal in developing antiasthmatic agents is based on two types of approaches: either anti-inflammatory or bronchodilators. Biologic and most small molecules have been shown to modulate specific asthma endotypes, targeting thymic stromal lymphopoietin, tryptase, spleen tyrosine kinase (Syk), Janus kinase, PD-L1/PD-L2, GATA-3, and CD38 for the treatment and management of Th2 endotype asthma. Academic Press 2022 Article PeerReviewed Okwuofu, Emmanuel Oshiogwe and Chee, Audrey Hui Yong and Chee, Jonathan Woei Lim and Stanslas, Johnson (2022) Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma. Pharmacological Research, 181. art. no. 106280. pp. 1-15. ISSN 1043-6618 https://www.sciencedirect.com/science/article/pii/S1043661822002250?via%3Dihub 10.1016/j.phrs.2022.106280 |
| spellingShingle | Okwuofu, Emmanuel Oshiogwe Chee, Audrey Hui Yong Chee, Jonathan Woei Lim Stanslas, Johnson Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma |
| title | Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma |
| title_full | Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma |
| title_fullStr | Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma |
| title_full_unstemmed | Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma |
| title_short | Molecular and immunomodulatory actions of new antiasthmatic agents: exploring the diversity of biologics in Th2 endotype asthma |
| title_sort | molecular and immunomodulatory actions of new antiasthmatic agents exploring the diversity of biologics in th2 endotype asthma |
| work_keys_str_mv | AT okwuofuemmanueloshiogwe molecularandimmunomodulatoryactionsofnewantiasthmaticagentsexploringthediversityofbiologicsinth2endotypeasthma AT cheeaudreyhuiyong molecularandimmunomodulatoryactionsofnewantiasthmaticagentsexploringthediversityofbiologicsinth2endotypeasthma AT cheejonathanwoeilim molecularandimmunomodulatoryactionsofnewantiasthmaticagentsexploringthediversityofbiologicsinth2endotypeasthma AT stanslasjohnson molecularandimmunomodulatoryactionsofnewantiasthmaticagentsexploringthediversityofbiologicsinth2endotypeasthma |